4//SEC Filing
Jagpal Sukhi 4
Accession 0001209191-22-040271
CIK 0001290149other
Filed
Jun 30, 8:00 PM ET
Accepted
Jul 1, 4:42 PM ET
Size
30.3 KB
Accession
0001209191-22-040271
Insider Transaction Report
Form 4
Jagpal Sukhi
Chief Financial Officer
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2022-07-01−1,218→ 0 totalExercise: $263.20Exp: 2026-03-08→ Common Stock (1,218 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−5,000→ 0 totalExercise: $78.40Exp: 2029-03-04→ Common Stock (5,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−94,113→ 0 totalExercise: $13.31Exp: 2030-02-25→ Common Stock (94,113 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−30,000→ 0 totalExercise: $16.73Exp: 2031-03-15→ Common Stock (30,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−5,887→ 0 totalExercise: $12.15Exp: 2030-08-12→ Common Stock (5,887 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−3,859→ 0 totalExercise: $122.20Exp: 2025-03-18→ Common Stock (3,859 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−4,200→ 0 totalExercise: $72.80Exp: 2026-09-30→ Common Stock (4,200 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−1,750→ 0 totalExercise: $58.00Exp: 2027-03-06→ Common Stock (1,750 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−4,509→ 0 totalExercise: $94.40Exp: 2028-03-06→ Common Stock (4,509 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−49,000→ 0 totalExercise: $12.15Exp: 2030-08-12→ Common Stock (49,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−50,000→ 0 totalExercise: $31.54Exp: 2032-03-14→ Common Stock (50,000 underlying)
Footnotes (13)
- [F1]The option fully vested on February 2, 2019.
- [F10]On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.
- [F11]The option vested as to 25% of the total shares on August 10, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on August 10, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- [F12]The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.
- [F13]The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.
- [F2]Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger.
- [F3]The option fully vested on January 1, 2020.
- [F4]The option fully vested on September 30, 2019.
- [F5]The option fully vested on January 1, 2021.
- [F6]The option fully vested on January 1, 2022.
- [F7]The option vested as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.
- [F8]The option vested as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- [F9]Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
Documents
Issuer
Sierra Oncology, Inc.
CIK 0001290149
Entity typeother
Related Parties
1- filerCIK 0001554591
Filing Metadata
- Form type
- 4
- Filed
- Jun 30, 8:00 PM ET
- Accepted
- Jul 1, 4:42 PM ET
- Size
- 30.3 KB